Low-Dose Interleukin-2 Therapy: A Transformative Approach for the Management of Autoimmune Complications Associated with Streptococcus pyogenes Infections
Ailin Lepletier(Griffith University), Manisha Pandey(Griffith University), Michael F. Good(Griffith University), Harshi Weerakoon(The University of Queensland), Rukshan Ahamed Mohamed Rafeek(University of Peradeniya), Natkunam Ketheesan(University of New England), Despena Vedis(Griffith University)
Cited by 0
Related Papers
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
|Cancer Discovery|2019|272
CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells
|Immunity|2020|181
Hormonal control of T-cell development in health and disease
|Nature Reviews Endocrinology|2015|119
CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
|Cancer Immunology Research|2019|117
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma
|Clinical Cancer Research|2020|113